Would you offer PMRT to an ER/PR positive HER2 amplified early stage (node negative) breast cancer patient found to have less than pCR to neoadjuvant TCHP?

With TCHP, expected pCR is rare (around 25 to 30 percen) for ER positive breast ca and they derive benefit from anti estrogen therapy and I would not offer PMRT

Only one with node negative but less than pCR would consider for PMRT is triple negative especially if residual disease is more than 2 cm